Progenitor Cell Generation via Epithelial-Mesenchymal Transition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Obtaining sufficient quantities of undifferentiated progenitor cells and controlling their differentiation into specific cell types for cell-based therapies has been a challenge in biomedical research.
Innovation Solution
The method involves inducing epithelial-mesenchymal transition (EMT) in epithelial cells to generate progenitor cells, which can be isolated and propagated, and then differentiated into specific cell types by withdrawing the inducer, allowing for their use in cell-based therapies such as treating Parkinson's, Alzheimer's, and other diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If epithelial cells are induced to undergo epithelial-mesenchymal transition to generate progenitor cells, then the quantity of progenitor cells is increased, but the control over differentiation into specific cell types becomes more difficult
Solution Approach 1:
The patent applies parameter changes by modulating the expression levels of specific transcription factors (Snail, Slug, Twist, SIP1) to control the differentiation process. By adjusting the expression parameters of these master regulatory genes, the invention achieves both sufficient progenitor cell generation and precise directional differentiation into desired cell types such as cardiomyocytes, hepatocytes, or neurons.
Solution Approach 2:
The invention uses intermediary molecules including small molecule inhibitors and activators that target signaling pathways (TGF-β, Wnt, Notch) to mediate the differentiation process. These intermediaries provide precise control over cell fate decisions while allowing for the generation of sufficient progenitor cell populations, resolving the contradiction between quantity and control precision.
2Quantity of substance
If progenitor cells are maintained in an undifferentiated state for sufficient quantities, then the quantity of undifferentiated cells is increased, but the time required for therapeutic application is extended
Solution Approach 1:
The patent applies preliminary action by pre-differentiating progenitor cells into specific therapeutic cell types before transplantation. By using controlled expression of master regulatory genes and signaling pathway modulators, the invention generates sufficient quantities of undifferentiated cells rapidly, then directs their differentiation in advance to the desired cell type, reducing the overall time required for therapeutic application.
Solution Approach 2:
The invention maintains continuous useful action by establishing culture conditions and genetic modifications that allow sustained proliferation of undifferentiated progenitor cells without spontaneous differentiation. This continuous maintenance of the undifferentiated state enables accumulation of sufficient cell quantities while preserving the ability to rapidly initiate differentiation when needed, minimizing time loss.
Data Source
AI summary
Methods for preparing progenitor cells are described where epithelial cells are induced to undergo epithelial-mesenchymal transition as a result of exposure to an inducing agent or introduction of a gene therein that induces epithelial-mesenchymal transition. Progenitor cells resulting therefrom have use in cell-based therapies, among other utilities.